As we move into 2025, the pharmaceutical and biotech industries are experiencing a renewed surge in momentum. The outlook is increasingly positive, and the demand for specialized drug development and manufacturing services is rising. With investment dollars flowing back into the pipeline and development timelines accelerating, now is the critical time to secure your spot with a trusted CDMO partner.
Ascendia Pharmaceutical Solutions will be attending DCAT Week 2025 in New York City from March 17-20, and we are eager to meet with industry partners to discuss innovative solutions for complex drug development challenges. As a US-based specialty CDMO, Ascendia offers a comprehensive suite of formulation development, analytical and manufacturing services, all designed to accelerate projects from early development through commercialization. We support NCE, 505(b)(2) and complex generic programs for both small molecule and biologic candidates across a wide range of dosage forms, including injectable, oral, topical, and ophthalmic.
Why Meet with Ascendia at DCAT Week?
DCAT Week is one of the most significant business development venues for the global pharmaceutical industry. With this being the 97th annual DCAT event, it has established itself as a premier networking opportunity, bringing together leading pharmaceutical developers, CDMOs and API manufacturers from around the world. Unlike conventional conferences, DCAT is structured around scheduled, high-value meetings, allowing companies to engage in productive discussions tailored to their specific needs.
Ascendia has been a dedicated member of DCAT for years, and we continue to see its value in forging new partnerships and strengthening existing relationships. Over the course of four days, our team will be holding dozens of meetings at the InterContinental Barclay Hotel, providing insights into how our expertise and state-of-the-art technologies can help advance your drug development programs.
2025: A Defining Year for Drug Development
As the industry rebounded from an earlier slowdown, we have witnessed a renewed enthusiasm for investment in drug development. Events like January’s JP Morgan Healthcare Conference have already indicated a more optimistic outlook for the pharmaceutical space, with projects moving forward and an increasing demand for specialized CDMO services. As timelines tighten and competition intensifies, securing the right development partner early is more critical than ever.
The Ascendia Difference
Ascendia has evolved significantly since our founding in 2012. Today, we provide end-to-end CDMO solutions that tackle some of the most pressing challenges in formulation development and manufacturing, including:
- Advanced Nanotechnologies – We have capabilities to develop and manufacture amorphous solid dispersions, lipid nanoparticles (LNPs) and long-acting injectables (LAIs), among others. Our latest investments in cutting-edge nano-milling technology, fully calibrated to industry specifications, set us apart in the market. Clients looking for customized, precision-engineered drug formulations won’t find these capabilities anywhere else.
- Seamless In-House Integration – From formulation development to scale-up, manufacturing, analytical, and microbiological testing, we offer all services under one roof, eliminating inefficiencies and reducing time to market.
- Speed Without Compromise – We understand that time is of the essence in drug development. Our business model is designed to initiate projects in weeks rather than months, ensuring that your timeline stays on track.
- Simple Elegance – Ascendia only uses GRAS (Generally Recognized as Safe) materials when developing formulations based on its 4 core nanotechnology platforms. This ensures compliance without adding complexity or uncertainty to your program.
Secure Your Meeting – Space is Limited!
With the industry ramping back up, demand for our specialized services is increasing. To guarantee your spot in our development queue, we strongly encourage setting up a meeting in advance.
Our leadership team, including CEO Jim Huang and Chief Business Officer, Robert Bloder, will be on-site with other team members to discuss your projects. We are eager to explore how we can support your formulation and manufacturing needs in 2025 and beyond.
Meeting Location:
📅 Dates: March 17-20, 2025
InterContinental Barclay Hotel, New York City
📩 Contact Us: Reach out today to learn more and schedule a meeting with our team.
Book a Meeting Directly: Select a time and secure a meeting during DCAT.
Now is the time to secure a spot in line for your development and/or manufacturing needs. Let’s connect at DCAT Week and make 2025 a year of innovation and success!